COMMUNIQUÉS West-GlobeNewswire

Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 14:00

PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one [...]

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

05/09/2024 - 14:00

DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 14:00

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurodegenerative [...]

Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications

05/09/2024 - 14:00

Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 14:00

BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight [...]

Cidara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 14:00

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) [...]

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

05/09/2024 - 14:00

BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]

Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

05/09/2024 - 14:00

Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision [...]

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

05/09/2024 - 14:00

Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager [...]

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

05/09/2024 - 14:00

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program PALI-2108, an orally [...]

4DMT Announces Presentations at Upcoming Retina Conferences

05/09/2024 - 14:00

EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic [...]

Myriad Genetics to Host Investor Event on October 9, 2024

05/09/2024 - 14:00

SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central Hotel in New York [...]

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

05/09/2024 - 14:00

ARQ-255 is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for alopecia areata Proprietary Deep Dermal Drug Delivery (4D) technology formulated to deliver drug deep into [...]

Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

05/09/2024 - 14:00

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery [...]

Alignment Health Named One of Newsweek’s World’s Most Trustworthy Companies in 2024

05/09/2024 - 14:00

ORANGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Alignment Health , a consumer brand name of Alignment Healthcare, Inc. (NASDAQ: ALHC), has been recognized as one of Newsweek’s World’s Most Trustworthy Companies 2024 [...]

Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference

05/09/2024 - 14:00

WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]

Eccogene Appoints Glenn Reicin as Chief Financial Officer

05/09/2024 - 14:00

BOSTON, Mass. and SHANGHAI, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and [...]

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

05/09/2024 - 14:00

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

05/09/2024 - 14:00

NORWOOD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will [...]